Eyeworld

70 | EYEWORLD | APRIL 2023 R EFRACTIVE Contact Ryburn: cullen.ryburn@ vancethompsonvision.com Williamson: blakewilliamson@weceye.com Relevant disclosures Ryburn: None Williamson: Bausch + Lomb, Carl Zeiss Meditec, Johnson & Johnson Vision improvement from patient feedback, he said, but at the expense of near vision. Some patients were happy with blended Symfony and ZLB00, but the different higher order aberrations between the eyes caused significant nighttime visual complaints for some patients, Dr. Ryburn said, adding that newer trifocals and the Light Adjustable Lens (LAL, RxSight) have been a step forward in visual range, quality, and happiness. However, Dr. Ryburn noted that there are some scenarios where he will still mix and match. "Currently, I am most likely to mix and match IOLs if there is an ocular pathology limit- ing vision. For example, someone with a corneal scar causing irregular astigmatism in one eye may be a good candidate for a small aperture lens (i.e., IC-8 Apthera [Bausch + Lomb]) in one eye with a different technology lens in the fellow eye. Another example is a patient with a history of refractive amblyopia who has worn a multifocal contact lens happily in the past and is highly motivated for spectacle independence. In that situation, I would be comfortable offering an EDOF or trifocal lens in the eye with good visual potential and consider a monofocal or monofocal toric in the amblyopic eye depending on visual potential." Dr. Williamson said the advent of the LAL has added a component of mixing and match- ing, although "technically it's not mixing and matching because it's the LAL in both eyes." He added that he's had success doing micro-mono- vision with the LAL. "We understand that when- ever you do adjustments on the LAL, you build in a bit of depth of focus, and by targeting the non-dominant eye at –0.75 or something like that, you tend to get good near vision," he said. Dr. Ryburn agreed that the LAL has been a great technology for achieving spectacle inde- pendence by blending the non-dominant eye into a mini-monovision eye. "By targeting plano and adjusting the lens myopic, there is induc- tion of spherical aberration that allows for an extended depth of field," he said. "Typically, this allows for a significant retention of distance vi- sion in the non-dominant eye while also aiding near vision." Dr. Ryburn said another situation of blend- ing lenses includes a EDOF or trifocal lens in a patient who previously had a monofocal lens in the fellow eye. "With appropriate counseling, I have seen these patients be very happy with the extended visual range," he said. "One of the most exciting things has been the contin- ued development of new lens technologies that allow for customization of vision for patients. While we would seek a lens that is identical to our natural crystalline lens, we are closer to this goal than we ever have been and continue to make strides every day." In the future, Dr. Williamson expects to see more options from the pipeline. He noted innovations from STAAR Surgical in presby- opia-correcting lenses. He also suggested that an improvement to the Eyhance lens (Johnson & Johnson Vision) could be beneficial. "If they could figure out a way to make it a premium lens and make it so there's more near vision, I could see the Eyhance taking off where you can do that in both eyes." Dr. Williamson thinks that mixing and matching is a good option for surgeons to have and said that it doesn't need to be controversial. "I'm always stunned by the fact that doctors are so hesitant to mix and match, and my comment to them is you're already mixing and matching. You've been mixing and matching since the day you did cataract surgery because every eye is different. You're doing biometry and putting a different power lens in each eye," he said. "I think the stigma or confusion needs to go away because I think it's here to stay." continued from page 69 "One of the most exciting things has been the continued development of new lens technologies that allow for customization of vision for patients. While we would seek a lens that is identical to our natural crystalline lens, we are closer to this goal than we ever have been and continue to make strides every day." —Cullen Ryburn, MD

• Blank Page
• Blank Page (1)